Pancreatic cancer detection reagent, pancreatic cancer detection kit, pancreatic cancer detection device and application

A detection reagent and a technology for pancreatic cancer, applied in the field of pancreatic cancer detection reagents, to achieve the effects of long survival period, good specificity and high detection sensitivity

CN110456054AActive Publication Date: 2019-11-15ZHENYUE BIOTECHNOLOGY JIANGSU CO LTD
5 Cites 6 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2019-11-15

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides a pancreatic cancer detection reagent, a pancreatic cancer detection kit, a pancreatic cancer detection device and application. The detection reagent comprises antibodies of anytwo or more of the following molecular markers, wherein CD3, CD4, CD8 and CD68 belong to a group A, CD11b, CD14, CD33, CD45RO, CD57, CD66b, CD163, FoxP3, LAG3, PD1, PDL1, TIGIT, panCK and TIM3 belongto a group B, and at least one molecular marker is selected from the group B. Detecting pancreatic cancer through the antibodies of two or more of the molecular markers provided by the invention hasthe advantages of high detection sensitivity and excellent specificity. Thus, the molecular markers are suitable for a multiple immunohistochemistry method to detect tumor microenvironment of a pancreatic cancer patient and are very advantageous, and consequently, whether the patient has a longer lifetime can be accurately predicted relatively, namely, prognosis is better.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the field of multiple immunohistochemical detection, in particular to a pancreatic cancer detection reagent, kit, device and application. Background technique

[0002] The existing immunohistochemistry commonly used diaminobenzidine (ie 3,3,-diaminobenzidine, DAB) color development, the principle is because diaminobenzidine is the chromogenic substrate of peroxidase, in the presence of hydrogen peroxide Under the condition of electron loss, the color change accumulates, forming a tan insoluble product. DAB is mainly combined with the NH2 or SH group of the protein to form a stable N-N bond or N-S bond, and then the chromogenic group in DAB can display the color and mark it on the exposed protein, thereby showing the protein distribution of the target cell and types etc. The prior art generally marks one molecule on one slice.

[0003] Multiple immunohistochemical (mIHC, multiple immno) analysis: multiple immune cells and imm...

Examples

Embodiment 1

[0102] Tumor tissues of 20 pancreatic cancer patients were selected: 10 cases each with shorter survival (sample number 1-10) and better survival (sample number 11-20 months) (overall survival (OS), specific survival See Table 1 for period.

[0103] Table 1. Survival period of 20 lung cancer patients

[0104] sample number 1 2 3 4 5 6 7 8 9 10 OS / month 5 6 8 8 8 10 10 11 12 12 sample number 11 12 13 14 15 16 17 18 19 20 OS / month 20 21 22 22 22 24 26 26 35 51

[0105] Multiplex immunohistochemical analysis of immune cells and immune checkpoint molecular detection was performed on the paraffin sections of tumor tissues of the above 20 cases. Each patient had 6 slices, a total of 6 staining panels, and a total of 18 molecules were labeled. The staining order of each molecule in 18 dyed molecules and 6 panels is:

[0106] Panel1: CD163, CD68, CD4, CD8, CD3;

[0107]Panel2: CD163, CD68, PDL1, CD8, PD1, CD57; ...